SCHEMBL4776552

SCHEMBL4776552

CS(=O)(=O)N(Cc1c(F)cccc1Cl)c1ccc(N(C=O)Cc2ccc(C(F)(F)F)nc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.39
MCOLN3 Q8TDD5 1/20 0.39
LMNA P02545 3/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NR1H2 P55055 7/20 0.36
NR1H3 Q13133 7/20 0.36
GPBAR1 Q8TDU6 1/20 0.36
NPC1 O15118 1/20 0.36
KCNA5 P22460 1/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
KCNH2 Q12809 1/20 0.34
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772347 0.86 GAA (0.37) POLBLMNAGAANR1H2NR1H3
SCHEMBL5571164 0.86 GAA (0.44) POLBLMNAALDH1A1GAAHTT
SCHEMBL4772420 0.86 GAA (0.37) POLBLMNAGAANR1H2NR1H3
SCHEMBL4776872 0.85 RECQL (0.39) POLBLMNAALDH1A1HTTNR1H2
SCHEMBL5571422 0.84 LMNA (0.40) POLBLMNAKDM4EALDH1A1HTT
SCHEMBL4775075 0.83 CNR2 (0.37) POLBLMNAKDM4EALDH1A1NR1H2
SCHEMBL5571607 0.82 CNR1 (0.37) LMNAKDM4EALDH1A1GAANR1H2
SCHEMBL4771131 0.82 GAA (0.37) POLBALDH1A1GAANR1H2NR1H3
SCHEMBL4770843 0.82 LMNA (0.36) POLBLMNAKDM4EALDH1A1GAA
SCHEMBL4777509 0.82 CNR2 (0.37) POLBLMNAKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 POLB 292/4885MCOLN3 1462/4885LMNA 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.